Organogenesis (NASDAQ:ORGO) Shares Down 3.8% – Time to Sell?

Organogenesis Holdings Inc. (NASDAQ:ORGO) shares traded down 3.8% during trading on Monday . The stock traded as low as $4.15 and last traded at $4.10. 158,757 shares changed hands during trading, a decline of 86% from the average session volume of 1,110,966 shares. The stock had previously closed at $4.26.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley lifted their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th.

Organogenesis Stock Performance

The stock has a 50 day moving average of $4.32 and a 200 day moving average of $3.69. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The firm has a market cap of $537.75 million, a price-to-earnings ratio of -70.67 and a beta of 1.79.

Insider Activity

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. This represents a 13.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 36.90% of the company’s stock.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently made changes to their positions in ORGO. Captrust Financial Advisors acquired a new stake in Organogenesis in the third quarter valued at approximately $36,000. Virtu Financial LLC acquired a new position in shares of Organogenesis during the fourth quarter worth $38,000. Merit Financial Group LLC bought a new position in shares of Organogenesis in the 1st quarter valued at $45,000. Palumbo Wealth Management LLC acquired a new stake in shares of Organogenesis during the 4th quarter valued at $65,000. Finally, ProShare Advisors LLC grew its position in Organogenesis by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company’s stock worth $65,000 after acquiring an additional 6,689 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.